Design of TNFR peptide agonists for inducing receptor oligomerization and cell apoptosis

Yi-Xuan Liu1,2, Hao Wang1,2

  • 1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, China. wanghao@nanoctr.cn.

Chemical Communications (Cambridge, England)
|June 25, 2025
PubMed

Insights

Researchers developed novel peptide agonists targeting Tumor Necrosis Factor Receptors (TNFRs) to combat chemotherapy-resistant cancers. These peptides induce apoptosis in cancer cells, showing significant therapeutic potential.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cancer Therapeutics
  • Drug Discovery

Background:

  • Tumor Necrosis Factor Receptors (TNFRs) are crucial in cancer therapy, especially for drug-resistant cells inducing p53-independent apoptosis.
  • Targeting TNFRs offers a promising strategy for overcoming treatment resistance in malignancies.

Purpose of the Study:

  • To design and characterize novel peptide agonists targeting CD95 and death receptor 5 (DR5) for cancer treatment.
  • To investigate the therapeutic potential of these peptides against treatment-resistant cancer cells.

Main Methods:

  • Utilized beta-sheet structures from FasL and TRAIL as scaffolds for peptide design.
  • Employed computational design and AlphaFold3 analysis to identify lead peptides (W10, AP, EIA, EPR).
  • Assessed binding affinities (bio-layer interferometry), conformational changes (circular dichroism), specificity, and cellular efficacy (IC50 values).

Main Results:

  • Identified four lead peptides with nanomolar to micromolar binding affinities for CD95 and DR5.
  • Confirmed target specificity and nanocluster formation upon receptor engagement.
  • Demonstrated micromolar IC50 values against colorectal and breast cancer cell lines, inducing NF-κB translocation and apoptosis.

Conclusions:

  • Developed a novel ligand-derived scaffold approach for creating TNFR peptide agonists.
  • These peptides show significant therapeutic potential against treatment-resistant malignancies.
  • The strategy offers a new avenue for developing targeted cancer therapies.

Related Concept Videos

The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.2K
Phagocytosis of Apoptotic Cells01:17

Phagocytosis of Apoptotic Cells

Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or  immature dendritic cells. Non-professional phagocytes such as  epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes. 
Normal cells contain receptors that prevent them from being recognized...
4.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K